Selective vitamin D receptor activator paricalcitol effectively reduce proteinuria in patients with type 2 diabetes through inhibition of the renin-angiotensin-aldosterone system (RAAS) [12]. The gene discussed is VDR; the disease is type 2 diabetes mellitus.